Endocyte Inc - Articles and news items

Merck logo

Merck and Endocyte announce independent DSMB recommends vintafolide PROCEED Phase 3 trial be stopped for futility following interim analysis

Industry news / 2 May 2014 / Merck

Merck and Endocyte, Inc. announced that the Data Safety Monitoring Board of the PROCEED trial has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped…

Merck logo
Merck logo

Exclusive worldwide agreement to develop and commercialize Phase III cancer candidate vintafolide (EC145)

Industry news, News / 16 April 2012 / Merck

Vintafolide is currently being evaluated in a Phase III clinical trial…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...